{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [["Lewy bodies", "Parkinson's disease", "mirtazapine", "psychosis", "visual hallucinations"]], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "23909968", "DateCompleted": {"Year": "2014", "Month": "02", "Day": "12"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "02"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1111/j.1479-8301.2012.00432.x"], "ArticleDate": [], "Journal": {"ISSN": "1479-8301", "JournalIssue": {"Volume": "13", "Issue": "2", "PubDate": {"Year": "2013", "Month": "Jun"}}, "Title": "Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society", "ISOAbbreviation": "Psychogeriatrics"}, "ArticleTitle": "Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.", "Pagination": {"StartPage": "103", "EndPage": "107", "MedlinePgn": "103-7"}, "Abstract": {"AbstractText": ["Psychotic symptoms often occur as a complication in Parkinson's disease patients, and a set of criteria for Parkinson's disease with psychosis (PDPsy) has been established. Among these criteria, hallucinations are one of the specific symptoms, with visual hallucinations being the most common. While atypical antipsychotic agents are often used for the treatment of PDPsy, adverse effects, including extrapyramidal symptoms, often hinder its continuation or tolerance. There have been some reports and reviews indicating that antidepressants may be effective for PDPsy and other forms of dementia with psychosis. In this report, we present a patient with PDPsy who was treated with one of the new-generation antidepressants, mirtazapine. Mirtazapine improved the patient's refractory psychotic symptoms, especially her visual hallucinations, without worsening her motor symptoms."], "CopyrightInformation": "\u00a9 2013 The Authors. Psychogeriatrics \u00a9 2013 Japanese Psychogeriatric Society."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Psychiatry, Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, Japan. k-tagai@jikei.ac.jp"}], "Identifier": [], "LastName": "Tagai", "ForeName": "Kenji", "Initials": "K"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Nagata", "ForeName": "Tomoyuki", "Initials": "T"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Shinagawa", "ForeName": "Shunichiro", "Initials": "S"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Tsuno", "ForeName": "Norifumi", "Initials": "N"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Ozone", "ForeName": "Motohiro", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Nakayama", "ForeName": "Kazuhiko", "Initials": "K"}], "PublicationTypeList": ["Case Reports", "Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Psychogeriatrics", "NlmUniqueID": "101230058", "ISSNLinking": "1346-3500"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antidepressive Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiparkinson Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antipsychotic Agents"}, {"RegistryNumber": "250PJI13LM", "NameOfSubstance": "Mianserin"}, {"RegistryNumber": "A051Q2099Q", "NameOfSubstance": "Mirtazapine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aged, 80 and over"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antidepressive Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antiparkinson Agents"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antipsychotic Agents"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["drug therapy", "etiology", "psychology"], "DescriptorName": "Hallucinations"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["analogs & derivatives", "therapeutic use"], "DescriptorName": "Mianserin"}, {"QualifierName": [], "DescriptorName": "Mirtazapine"}, {"QualifierName": ["complications", "drug therapy"], "DescriptorName": "Parkinson Disease"}, {"QualifierName": ["drug therapy", "etiology", "psychology"], "DescriptorName": "Psychotic Disorders"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2012", "Month": "4", "Day": "2"}, {"Year": "2012", "Month": "6", "Day": "27"}, {"Year": "2012", "Month": "8", "Day": "9"}, {"Year": "2013", "Month": "8", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2013", "Month": "8", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "2", "Day": "13", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["23909968", "10.1111/j.1479-8301.2012.00432.x"]}}], "PubmedBookArticle": []}